New brain tumor drug under the microscope: does it improve daily life?

NCT ID NCT07240662

Recruiting now Disease control Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated Apr 25, 2026 · Updated 21 times

Summary

This study follows 150 adults with a specific type of slow-growing brain tumor (grade 2 glioma with an IDH mutation) who are taking the drug vorasidenib after surgery. The main goal is to see how the drug affects their quality of life, including symptoms like seizures. Researchers will also track how well the drug controls the tumor and any side effects. This is an observational study, meaning doctors do not assign the treatment—they simply watch what happens in routine care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
RECRUITING

Heidelberg, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GLIOMA